Aromaticin

Aromaticin

SCHEMBL29399080

C=C1C(=O)O[C@H]2C[C@@H](C)[C@@H]3C=CC(=O)[C@@]3(C)C[C@H]12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 1.00
▸ RAB9A P51151 5/20 1.00
▸ NPC1 O15118 4/20 1.00
▸ HTT P42858 4/20 1.00
▸ XBP1 P17861 3/20 1.00
▸ MDM2 Q00987 3/20 1.00
▸ RECQL P46063 2/20 0.72
▸ PKM P14618 1/20 0.72
▸ POLB P06746 4/20 0.59
▸ MAPK1 P28482 3/20 0.59
▸ AGTR1 P30556 3/20 0.59
▸ GPR55 Q9Y2T6 3/20 0.59
▸ TERT O14746 1/20 0.59
▸ ALDH1A1 P00352 1/20 0.59
▸ GLA P06280 1/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ TDP1 Q9NUW8 1/20 0.59
▸ PTGS2 P35354 3/20 0.55
▸ PAX8 Q06710 1/20 0.51
▸ THRB P10828 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aromaticin SCHEMBL22198794 1.00 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1
Aromaticin SCHEMBL30237568 1.00 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1
Aromaticin SCHEMBL23601536 1.00 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1
SCHEMBL12682742 0.84 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1
Helenalin SCHEMBL11030579 0.74 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1
Helenalin SCHEMBL10132557 0.74 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1
Helenalin SCHEMBL31237389 0.74 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1
Helenalin SCHEMBL161594 0.74 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1
Helenalin SCHEMBL161593 0.74 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1
Helenalin SCHEMBL10099625 0.74 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3226919-B1 NEUTRALIZATION OF ODORS SADOVSKY LTD (IL) 2025-10-22 — — EP claimed
US-12240922-B1 Transition metal complex assisted green hydrolysis for nanocellulose extraction UNITED ARAB EMIRATES UNIVERSITY (AE) 2025-03-04 — — US claimed
CN-119112731-A Inula helveticus extract and preparation method and application thereof 南京中医药大学 2024-12-13 — — CN claimed
WO-2024128863-A1 ANODE MATERIAL FOR LITHIUM ION CELL 포스코홀딩스 주식회사 2024-06-20 — — WO claimed
EP-4308664-A1 HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES Merck Patent GmbH (DE) 2024-01-24 — — EP claimed
US-11739066-B2 Method for fluoroalkylation of enamines ARXADA AG (CH) 2023-08-29 — — US claimed
CN-116391908-A Filling material for improving smoking taste of cigarettes and preparation method and application thereof 广东中烟工业有限责任公司 2023-07-07 — — CN claimed
CN-111712589-B Electroless palladium plating solution and palladium plating film 上村工业株式会社 2022-10-04 — — CN claimed
WO-2022194799-A1 HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2022-09-22 — — WO claimed
US-20220204464-A1 Method for Fluoroalkylation of Enamines LONZA LTD (CH) 2022-06-30 — — US claimed
CN-110997851-B Allyl-functionalized urethane oligomers and related compositions for coatings and adhesives 阿科玛法国公司 2022-06-07 — — CN claimed
EP-3983381-A1 METHOD FOR FLUOROALKYLATION OF ENAMINES Arxada AG (CH) 2022-04-20 — — EP claimed
US-11261288-B2 Allyl functional urethane oligomers and related compositions for coatings and adhesives ARKEMA FRANCE (FR) 2022-03-01 — — US claimed
EP-4746916-A2 CLEAVABLE POLYMER-DRUG CONJUGATES FOR ALZHEIMER'S DISEASE University of Utah Research Foundation (US) 2026-05-27 — — EP disclosed
EP-4233078-B1 NON-CURABLE SILICONE COMPOSITION COMPRISING CARBON BLACK MOMENTIVE PERFORMANCE MAT GMBH (DE) 2026-05-06 — — EP disclosed
EP-4735009-A1 FERRITIN-GOLD NANOPARTICLE CONJUGATES FOR PHOTODYNAMIC CANCER THERAPY Temple University Of The Commonwealth System Of Higher Education (US) 2026-05-06 — — EP disclosed
US-20220072138-A1 NRTI THERAPIES THE JOHNS HOPKINS UNIVERSITY 2022-03-10 — — US disclosed
US-11267783-B2 Composition and method for treating urea Crommelin Agricoatings Pty Ltd (AU) 2022-03-08 — — US disclosed
US-11261288-B2 Allyl functional urethane oligomers and related compositions for coatings and adhesives ARKEMA FRANCE (FR) 2022-03-01 — — US disclosed
WO-2022039850-A1 TOFACITINIB-CONTAINING ANHYDROUS ELASTOMER-BASED GEL FORMULATIONS VYNE THERAPEUTICS INC. (US) 2022-02-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220072138-A1 NRTI THERAPIES TK1, PNP, TYMP MAPT 1055/4885RAB9A 679/4885NPC1 1803/4885
US-11739066-B2 Method for fluoroalkylation of enamines HNMT, PNMT, INMT MAPT 3997/4885RAB9A 752/4885NPC1 959/4885
US-20220204464-A1 Method for Fluoroalkylation of Enamines HNMT, PNMT, INMT MAPT 3997/4885RAB9A 752/4885NPC1 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback